The systemic scleroderma treatment market is predicted to chart a notable growth trajectory over the forecast period from 2019 to 2029.
The systemic scleroderma treatment market is predicted to chart a notable growth trajectory over the forecast period from 2019 to 2029. Firstly, the additional approvals for presently used treatment options along with the first-in-class therapies that are in the pipeline are some primary factors fueling the systemic scleroderma treatment market. Lack of curative therapies and continued use of off-label drugs are underlying factors spurring interest of researchers and pharmaceutical companies in rare diseases.
The report provides growth analysis and revenue projections at a global, regional, and country level in the systemic scleroderma treatment market for the 2019 – 2029 forecast period. The report examines key segments within each category with their growth rate projections over the forecast period.
Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=7023
Systemic Scleroderma Treatment Market: Competitive Landscape
The systemic scleroderma treatment market is highly competitive due to vast unmet medical needs. Mergers and acquisitions, partnerships, and strategic alliances are some growth strategies large companies in the systemic scleroderma treatment market are adopting. For example, in 2017, Janssen Pharmaceutical Company – a subsidiary of Johnson and Johnson Services Inc., acquired Actelion Pharmaceuticals Ltd. to become the leading player in the field of pulmonary hypertension.
Some other prominent companies operating in the systemic scleroderma treatment market are Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Pfizer Inc., Gilead Sciences Inc., Novartis AG, and Bayer AG.
Systemic Scleroderma Treatment Market: Key Trends
Vast unmet medical needs for systemic scleroderma is one of the key factors spurring the systemic scleroderma treatment market. At present, off-label drugs such as the ones for symptomatic autoimmune disorders such as rheumatoid arthritis are used for the treatment of systemic scleroderma. This serves to fuel the development of small molecule combination therapies and targeted biologics, to present vast scope of growth for the systemic scleroderma treatment market.
Extensive efforts of researchers and sponsors who are focused on developing novel drug candidates at a rapid rate strengthens growth prospects of the systemic scleroderma treatment market. Development of drug candidates most of which are in the pipeline vary in terms of their type and mechanism of action. For example, in September 2020, Kadmon Holdings Inc. obtained Orphan Drug Designation by the U.S. FDA for its new drug, belumosudil – for the treatment of systemic scleroderma.
However, current unique challenges in drug development for systemic scleroderma hampers the growth of systemic scleroderma treatment market.
Systemic Scleroderma Treatment Market: Regional Assessment
North America stood at the fore in the systemic scleroderma treatment market in the recent past. Increasing penetration of biologics in developed countries is a key factor behind the growth of systemic scleroderma treatment market in North America. In addition, use of recently developed immunosuppressants and a favorable reimbursement scenario is another key driver of the North America systemic scleroderma treatment market.
Europe occupies lower share than North America mainly due to the use of biosimilars and generics for off-label treatment of systemic scleroderma. The U.K. is expected to witness significant growth in the systemic scleroderma treatment market in the years ahead. This is mainly because of launch of biologics and small molecules for the treatment of systemic sclerosis and associated indications.
Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=7023
About TMR Research
TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.
Contact:
Rohit Bhisey
TMR Research,
3739 Balboa St # 1097,
San Francisco, CA 94121
United States
Tel: +1-415-520-1050
Visit Site: https://www.tmrresearch.com/